Cyfuse Biomedical and Cyberdyne signed a $12 million deal to develop and market the Regenova 3D tissue printing system.

Cell Applications, Inc. and Cyfuse Biomedical K.K. have announced that advanced tissue-engineering services are now available in North America using a new three-dimensional (3D) bioprinting approach called the "Kenzan Method". Using Cyfuse Biomedical's Regenova® 3D Bio Printer, Cell Applications has created a pay-for-service bio-printing model that makes scaffold-free tissue available immediately to scientists in the U.S. and Canada for research use.

Researchers from Nagasaki University in Japan are working on scaffold-free approaches for an artificial trachea by assessing the circumferential tracheal replacement using scaffold-free trachea-like grafts, generated from isolated cells in an inbred animal model. Regenova 3D bioprinter from Cyfuse Biomedical was used to assemble multicellular spheroids in a tube-shaped artificial trachea.